133343Inactivation of Antibiotic Resistance in Clinical Isolates of Pathogenic EnterobacteriaceaeClosedFeasibility StudiesInnovate UKNemesis Bioscience has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established and safe antibiotics to be effective again. Resurrecting antibiotic susceptibility eliminates the threat of ‘super bugs’ and ensures current and newly developed antibiotics retain efficacy over the long-term. The company has proven that its “Nemesis Symbiotics” convert antimicrobial resistant (AMR) bacteria to antibiotic sensitivity and also prevent bacteria from acquiring AMR – presenting the possibility of protecting patients pre-operatively, or even pre-admission, to lower the risks of subsequent AMR infection. In the current study the company will complete experimental work to validate its technology in pathogenic bacteria isolated from clinical infections and demonstrate that its Symbiotic technology can have real-world application for the treatment and prevention of infections with antibiotic resistant bacteria. The company’s products will have significantly shorter development times than existing antimicrobials. To date the company has raised funds from its founders, Angel investors, the Rainbow Seed Fund and from Finance Wales. The company won the King’s College, Cambridge Entrepreneurship Award for 2014.